JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $97

Benzinga Newsdesk www.benzinga.com Positive 68.8%

Neg 0% Neu 0% Pos 68.8%

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $92 to $97.